This study is examining the effects of standard of care cancer treatment as well as a medication called Sildenafil, on the cancer associated fatigue, cognition and the gut microbiome.
Age range
30 Years – 50 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Fatigue and Cognition as measured by the Fatigue and Altered Cognition Scale at baseline
Timeframe: Baseline
Fatigue and Cognition as measured by the Fatigue and Altered Cognition Scale after neoadjuvant chemotherapy treatment
Timeframe: through neoadjuvant chemotherapy treatment completion, average of 20 weeks from baseline
Fatigue and Cognition as measured by the Fatigue and Altered Cognition Scale after surgery
Timeframe: through completion of surgery, average of 24 weeks from baseline
Fatigue and Cognition as measured by the Fatigue and Altered Cognition Scale after radiation treatment
Timeframe: through radiation treatment completion, average of 30 weeks from baseline
Fatigue and Cognition as measured by the Fatigue and Altered Cognition Scale after chemotherapy treatment
Timeframe: through chemotherapy treatment completion, average of 50 weeks from baseline
Fatigue and Cognition as measured by the Fatigue and Altered Cognition Scale after 24 weeks of endocrine treatment
Timeframe: through 24 weeks of endocrine treatment, average of 74 weeks from baseline
Perceived Cognition measured by the Functional Assessment of Cancer Therapy - Cognitive (FACT-Cog) at baseline
Timeframe: baseline
Perceived Cognition measured by the Functional Assessment of Cancer Therapy - Cognitive (FACT-Cog) after neoadjuvant chemotherapy treatment
Timeframe: through neoadjuvant chemotherapy treatment completion, average of 20 weeks from baseline
Perceived Cognition measured by the Functional Assessment of Cancer Therapy - Cognitive (FACT-Cog) after surgery
Timeframe: through completion of surgery, average of 24 weeks from baseline
Perceived Cognition measured by the Functional Assessment of Cancer Therapy - Cognitive (FACT-Cog) after radiation treatment
Timeframe: through radiation treatment completion, average of 30 weeks from baseline
Perceived Cognition measured by the Functional Assessment of Cancer Therapy - Cognitive (FACT-Cog) after chemotherapy treatment
Timeframe: through chemotherapy treatment completion, average of 50 weeks from baseline
Perceived Cognition measured by the Functional Assessment of Cancer Therapy - Cognitive (FACT-Cog) after 24 weeks of endocrine therapy treatment
Timeframe: through 24 weeks of endocrine treatment, average of 74 weeks from baseline
Perceptual Fatigue as measured by the MD Anderson Brief Fatigue Inventory (BFI) at baseline
Timeframe: baseline
Perceptual Fatigue as measured by the MD Anderson Brief Fatigue Inventory (BFI) after neoadjuvant chemotherapy treatment
Timeframe: through neoadjuvant chemotherapy treatment completion, average of 20 weeks from baseline
Perceptual Fatigue as measured by the MD Anderson Brief Fatigue Inventory (BFI) after surgery
Timeframe: through completion of surgery, average of 24 weeks from baseline
Perceptual Fatigue as measured by the MD Anderson Brief Fatigue Inventory (BFI) after radiation treatment
Timeframe: through radiation treatment completion, average of 30 weeks from baseline
Perceptual Fatigue as measured by the MD Anderson Brief Fatigue Inventory (BFI) after chemotherapy treatment
Timeframe: through chemotherapy treatment completion, average of 50 weeks from baseline
Perceptual Fatigue as measured by the MD Anderson Brief Fatigue Inventory (BFI) after 24 weeks of endocrine treatment
Timeframe: through 24 weeks of endocrine treatment, average of 74 weeks from baseline